Skip to main content
. Author manuscript; available in PMC: 2022 Apr 1.
Published in final edited form as: Cancer Res. 2021 Aug 4;81(19):5102–5114. doi: 10.1158/0008-5472.CAN-21-0524

Figure 3. BT-GSI decreases tumor growth and the number of proliferating MM cells.

Figure 3.

(a) Experimental design (105 5TGM1 MM cells, IT-intratibial injection). Effects of zoledronic acid (ZA, 0.1 mg/kg, two times a week, for 3 weeks) and equimolar dosing (0.1mol/L, three times a week, 3 weeks) of GSI, BT, and BT-GSI on (b) serum levels of the 5TGM1 tumor biomarker IgG2b, and (c) on bone tumors (week 6) stained for Proliferating Cell Nuclear Antigen (PCNA). Bars represent means ± SD. n=6-11/group. *p<0.05 vs. week 3 (c). Representative immunostaining images per group are shown. Red dotted lines delimit bone tissue. The horizontal dotted line indicates the mean value for vehicle-treated mice bearing MM tumors.